Article
Li et al.
plexes were determined by direct methods procedures in
SHELXS,18 and refined by full-matrix least-squares meth-
ods, on F2’s, in SHELXL.19
able microplate reader (Molecular Devices, Sunnyvale,
CA, USA) at 570 nm. The relative cell viability (%) related
to control wells containing cell culture medium without
samples was calculated by A570 nm [sample]/A570 nm [con-
trol] ´ 100.
Cell Culture
Human lung carcinoma cells (A549 cells) and human
hepatoblastoma cell (Hep3B cells and HepG2 cells) were
obtained from the Bioresource Collection and Research
Center (BCRC, Food Industry Research and Development
Institute, Hsinchu, Taiwan). Human hepatocellular carci-
noma cells (Huh7 cells and PLC5 cells) were obtained from
the American Type Culture Collection (ATCC, Bethesda,
MD, USA). Human colorectal carcinoma cells (COLO 205
cells and HT-29 cells) were provided by Dr Min-Hsiung
Pan (National Kaohsiung Marine University, Kaohsiung,
Taiwan). A549 cells were grown in a medium consisting of
90% RPMI 1640 with 10% fetal bovine serum supple-
mented with 0.1 mM nonessential amino acid, 2 mM L-
glutamine, 1 mM sodium pyruvate, and 100 units/mL peni-
cillin/streptomycin. COLO 205 cells and HT-29 cells were
grown in 90% RPMI 1640 medium supplemented with
10% fetal bovine serum, 100 units/mL penicillin, and 100
mg/mL streptomycin. Hep3B cells, HepG2 cells, Huh7
cells, and PLC5 cells were grown in 90% Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 0.1
mM non-essential amino acids, 1.0 mM sodium pyruvate,
100 units/mL penicillin, and 100 mg/mL streptomycin. Hu-
man cancer cells were cultured at 37 °C in a humidified 5%
CO2 incubator. Human cancer cells were treated with 50
mM compounds 1 and 2 for 48 h.
ACKNOWLEDGMENT
We acknowledge the financial assistance to the Na-
tional Science Council of Taiwan. We would also like to
thank the National Changhua University of Education for
supporting the X-ray diffractometer and NMR spectrome-
ter.
REFERENCES
1. Gaykema, W. P. J.; van Schaik, E. J. M.; Schutter, W. G.; Hol,
W. G. H. Chem. Scr. 1983, 21, 199.
2. (a) Averill, B. A.; Chandhuri, A. P.; Hendrix, D. C.; Silvis, H.
C. Cienc. Biol. Mol. Cell Biol. 1980, 5, 167. (b) Birker, P. J.
M. W. L.; Godefroi, E. F.; Helder, J.; Reedijk, J. J. Am.
Chem. Soc. 1982, 104, 7556. (c) Addison, A. W.; Hendriks,
H. M. J.; Reedijk, J.; Thompson, L. K. Inorg. Chem. 1981,
20, 103. (d) Karlin, K. D.; Hayes, J. C.; Hutchinson, J. P.;
Hyde, J. R.; Zubieta, J. Inorg. Chim. Acta 1983, 79, 198. (e)
Gagnê, R. R.; Kreh, R. P.; Dodge, J. A.; Marsh, R. E.;
McCool, M. Inorg. Chem. 1982, 21, 254.
3. (a) Sorell, T. N.; Jameson, D. L. Inorg. Chem. 1982, 21,
1014. (b) Bertini, I.; Canti, G.; Luchinat, C.; Mani, F. Inorg.
Chem. 1981, 20, 1670.
4. Trofimenko, S. Chem. Rev. 1993, 93, 943.
5. Monica, G. L.; Ardizzoia, G. A. Prog. Inorg. Chem. 1997, 46,
151.
6. Ehlert, M. K.; Rettig, S. J.; Storr, A.; Thompson, R. C.; Trot-
ter, J. Can. J. Chem. 1990, 68, 1444.
Cell Viability by MTT Assay
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphen-
yl tetrazolium bromide] (Sigma Chemical Co., St. Louis,
MO, USA) assay was performed according to the method
of Mosmann.20 Cancer cells were plated into 96-well mi-
crotiter plates at a density of 1 ´ 104 cells/well. After 24 h,
culture medium was replaced by 200 mL (50 mM) of com-
pounds 1 and 2, and the cells were incubated for 48 h. The
final concentration of solvent was less than 0.1% in cell
culture medium. Culture medium was removed and re-
placed by 90 mL fresh culture medium. Ten microliters of
sterile filtered MTT solution (5 mg/mL) in phosphate buf-
fered saline (PBS, pH = 7.4) was added to each well,
thereby reaching a final concentration of 0.5 mg MTT/mL.
After 5 h, unreacted dye was removed, and the insoluble
formazan crystals were dissolved in 200 mL/well DMSO
and measured spectrophotometrically in a VersaMax tun-
7. (a) Gavrilova, A. L.; Bosnich, B. Chem. Rev. 2004, 104, 349.
(b) Bouwman, E.; Driessen, W. L.; Reedijk, J. Coord. Chem.
Rev. 1990, 104, 143. (c) Mishra, V.; Lloret, F.; Mukherjee, R.
Eur. J. Inorg. Chem. 2007, 2161. (d) Guerrero, A. M.; Jalon,
F. A.; Manzano, B. R.; Claramunt, R. M.; Marýa, M. D. S.;
Escolastico, C.; Elguero, J.; Rodrýguez, A. M.; Maestro, M.
A.; Mahia, J. Eur. J. Inorg. Chem. 2002, 3178. (e) Chou, C.
C.; Su, C. C.; Yeh, A. Inorg. Chem. 2005, 44, 6122. (f)
Prokofieva, A.; Prikhodko, A. I.; Enyedy, E. A.; Farkas, E.;
Maringgele, W.; Demeshko, S.; Dechert, S.; Meyer, F. Inorg.
Chem. 2007, 46, 4298. (g) Karlin, K. D.; Zubieta, J. Copper
Coordination Chemistry; Biochemical and Inorganic Per-
spectives; Adenine: Guilderland, NY, 1983.
8. Vattemi, E.; Claudio, P. P. Drug. News Perspect. 2007, 20,
511.
9. Zimmermann, K. C.; Bonzon, C.; Green, D. R. Pharmacol.
Ther. 2001, 92, 57.
702
© 2012 The Chemical Society Located in Taipei & Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
J. Chin. Chem. Soc. 2012, 59, 696-703